Pfizer halts study of lymphoma drug unlikely to help survival

(Reuters) - Pfizer Inc, which has been on a hot streak with three recent approvals of cancer drugs, stumbled on Monday, saying it was halting a late-stage trial of a drug for aggressive non-Hodgkin lymphoma after independent monitors found it was not likely to improve survival.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news